hydroxyurea has been researched along with Cancer of Pancreas in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 9.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| " The purpose of the current study was to determine whether dose intensification of parenteral hydroxyurea in combination with fluorouracil could enhance the response rates of the combination against refractory upper gastrointestinal malignancies." | 6.71 | Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. ( Haynes, H; Kaleya, R; Kaubisch, A; Rozenblit, A; Wadler, S, 2004) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 5.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| " The purpose of the current study was to determine whether dose intensification of parenteral hydroxyurea in combination with fluorouracil could enhance the response rates of the combination against refractory upper gastrointestinal malignancies." | 2.71 | Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. ( Haynes, H; Kaleya, R; Kaubisch, A; Rozenblit, A; Wadler, S, 2004) |
| " Pharmacodynamic studies were performed to assess drug effects on levels of deoxyuridine triphosphate (dUTP) and thymidine triphosphate (TTP) pools in peripheral-blood mononuclear cells (PBMCs) before and 6 hours after treatment using a highly sensitive DNA polymerase assay." | 2.69 | Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract. ( Berkenblit, R; Damle, S; Haynes, H; Kaleya, R; Ladner, RD; Murgo, A; Schechner, R; Wadler, S, 1999) |
| "Gemcitabine was combined with hydroxyurea or small interfering RNA targeting ribonucleotide reductase to assess changes in chemoresistance." | 1.38 | Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase. ( Funamizu, N; Kamata, Y; Lacy, CR; Manome, Y; Misawa, T; Uwagawa, T; Yanaga, K, 2012) |
| "After establishment of pancreatic cancer, groups 1 and 5 received no therapy, groups 2 and 6 were fed 7 mg Celebrex daily, groups 3 and 7 were given 28 mg Zyflo and groups 4 and 8 received Celebrex and Zyflo orally daily in weeks 17-32." | 1.31 | Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. ( Achucarro, P; Guski, H; Heinicken, D; Jacobi, CA; Kilian, M; Müller, JM; Schimke, I; Wenger, FA, 2002) |
| "11." | 1.31 | Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters. ( Bisevac, M; Guski, H; Khodadayan, C; Kilian, M; Müller, JM; Schimke, I; von Seebach, M; Wenger, FA, 2002) |
| "PAb421 reacted with all human pancreatic cancer cell lines but not with the hamster cells." | 1.29 | Comparison of p53 protein expression and cellular localization in human and hamster pancreatic cancer cell lines. ( Chaney, WG; Hirota, M; Mogaki, M; Pour, PM, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Du, R | 1 |
| Sullivan, DK | 1 |
| Azizian, NG | 1 |
| Liu, Y | 1 |
| Li, Y | 1 |
| Kato, T | 1 |
| Ono, H | 1 |
| Fujii, M | 1 |
| Akahoshi, K | 1 |
| Ogura, T | 1 |
| Ogawa, K | 1 |
| Ban, D | 1 |
| Kudo, A | 1 |
| Tanaka, S | 1 |
| Tanabe, M | 1 |
| Zhou, GX | 1 |
| Ding, XL | 1 |
| Wu, SB | 1 |
| Zhang, HF | 1 |
| Cao, W | 1 |
| Qu, LS | 1 |
| Zhang, H | 1 |
| Funamizu, N | 1 |
| Kamata, Y | 1 |
| Misawa, T | 1 |
| Uwagawa, T | 1 |
| Lacy, CR | 1 |
| Yanaga, K | 1 |
| Manome, Y | 1 |
| Wenger, FA | 3 |
| Kilian, M | 3 |
| Achucarro, P | 1 |
| Heinicken, D | 1 |
| Schimke, I | 3 |
| Guski, H | 2 |
| Jacobi, CA | 2 |
| Müller, JM | 2 |
| Bisevac, M | 1 |
| Khodadayan, C | 1 |
| von Seebach, M | 1 |
| Kaubisch, A | 1 |
| Kaleya, R | 2 |
| Haynes, H | 2 |
| Rozenblit, A | 1 |
| Wadler, S | 2 |
| Gregor, JI | 1 |
| Heukamp, I | 1 |
| Kiewert, C | 1 |
| Kristiansen, G | 1 |
| Walz, MK | 1 |
| Mogaki, M | 1 |
| Hirota, M | 1 |
| Chaney, WG | 1 |
| Pour, PM | 1 |
| Haaz, MC | 1 |
| Fischel, JL | 1 |
| Formento, P | 1 |
| Renée, N | 1 |
| Etienne, MC | 1 |
| Milano, G | 1 |
| Gebbia, V | 1 |
| Majello, E | 1 |
| Testa, A | 1 |
| Pezzella, G | 1 |
| Giuseppe, S | 1 |
| Giotta, F | 1 |
| Riccardi, F | 1 |
| Fortunato, S | 1 |
| Colucci, G | 1 |
| Gebbia, N | 1 |
| Raymond, E | 1 |
| de Gramont, A | 1 |
| Louvet, C | 1 |
| Tournigand, C | 1 |
| Demuynck, B | 1 |
| Beerblock, K | 1 |
| Carola, E | 1 |
| Krulik, M | 1 |
| Damle, S | 1 |
| Schechner, R | 1 |
| Berkenblit, R | 1 |
| Ladner, RD | 1 |
| Murgo, A | 1 |
| Lokich, JJ | 1 |
| Pitman, SW | 1 |
| Skarin, AT | 1 |
4 trials available for hydroxyurea and Cancer of Pancreas
| Article | Year |
|---|---|
Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 2004 |
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Topics: Adenocarcinoma; Administration, Oral; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1997 |
Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxyurac | 1999 |
10 other studies available for hydroxyurea and Cancer of Pancreas
| Article | Year |
|---|---|
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Ce | 2021 |
Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells.
Topics: Aged; Cell Line, Tumor; Cell Survival; Cytoplasm; Deoxycytidine; Drug Resistance, Neoplasm; Drug Syn | 2021 |
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Arachidonate 5-Lipoxygenase; Cell Line, Tumor; Cell Prolifer | 2015 |
Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
Topics: Antigens, CD; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bi | 2012 |
Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Celecoxib; Cricetinae; Glutathione; Hydroxyurea; Inc | 2002 |
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cricetinae; Hydroxyurea; Lipid Peroxida | 2002 |
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cricetinae; Cyclooxygenase Inhibitors; Dinoproston | 2005 |
Comparison of p53 protein expression and cellular localization in human and hamster pancreatic cancer cell lines.
Topics: Animals; Blotting, Western; Cell Survival; Cricetinae; Hot Temperature; Humans; Hydroxyurea; Immunoh | 1993 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
Combined 5-fluorouracil and hydroxyurea therapy for gastrointestinal cancer.
Topics: Administration, Oral; Ataxia; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointe | 1975 |